Kymera Therapeutics

KYMRPhase 2

Watertown, United StatesFounded 2016kymeratx.com

Kymera Therapeutics is advancing a robust pipeline of PROTAC degraders targeting transcription factors, scaffolding proteins, and other previously undruggable proteins across oncology, immunology, and other therapeutic areas. The company has built a proprietary platform combining computational chemistry, structural biology, and proteomics to design selective protein degraders. With multiple programs in clinical development and strategic partnerships with leading pharmaceutical companies, Kymera is positioned as a leader in the emerging protein degradation field.

Market Cap

$6.4B

Founded

2016

Employees

100-200

Focus

Biotech

KYMR · Stock Price

USD 77.91+37.48 (+92.70%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Pegasus platform for designing PROteolysis TArgeting Chimeras (PROTACs) that selectively degrade disease-causing proteins using the body's natural protein disposal system.

Pipeline Snapshot

9 drugs in pipeline

Drug	Indication	Stage
KT-621	Eosinophilic Asthma	Phase 2
KT-621	Atopic Dermatitis	Phase 2
KT-474/Placebo + KT-474	Healthy Volunteer	Phase 1
KT-253	Myeloid Malignancies	Phase 1
KT-621 + Placebo	Healthy Participants Study	Phase 1

Funding History

Total raised: $371.6M

IPO$173.6MUndisclosedAug 13, 2020

Series C$102MWellington ManagementJul 15, 2020

Series B$65MBessemer Venture PartnersJan 15, 2019

Series A$31MAtlas VentureOct 15, 2017

Opportunities

Kymera is positioned to capitalize on the large market of undruggable proteins through its advanced PROTAC platform and multiple clinical programs.

The company has significant expansion opportunities across therapeutic areas as protein degradation technology validates clinically.

Risk Factors

Key risks include clinical trial failures for novel protein degradation mechanism, increasing competition in the PROTAC space, and potential manufacturing complexities.

The company must demonstrate clinical proof-of-concept to validate the protein degradation approach.

Competitive Landscape

Kymera competes with other protein degradation companies like Arvinas, C4 Therapeutics, and Nurix Therapeutics. The company differentiates through its comprehensive Pegasus platform, focus on immunology targets, and advanced clinical pipeline with multiple programs in human trials.

Publications

Patents

Pipeline